References
Porter L (2006) Blue Trane. La vita e la musica di John Coltrane Minimum Fax (eds.), EAN: 9788875211158, p 575
Dhaun N, Webb DJ (2019) Endothelins in cardiovascular biology and therapeutics. Nat Rev Cardiol. https://doi.org/10.1038/s41569-019-0176-3
Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T (1988) A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332(6163):411–415.
Deanfield J, Donald A, Ferri C, Giannattasio C, Halcox J, Halligan S, Lerman A, Mancia G, Oliver JJ, Pessina AC, Rizzoni D, Rossi GP, Salvetti A, Schiffrin EL, Taddei S, Webb DJ; Working Group on Endothelin and Endothelial Factors of the European Society of Hypertension. Endothelial function and dysfunction. Part I. Methodological issues for assessment in the different vascular beds: a statement by the Working Group on Endothelin and Endothelial Factors of the European Society of Hypertension. J Hypertens. 2005; 23(1):7–17
Ferri C, Properzi G, Tomassoni G, Santucci A, Desideri G, Giuliani AE, Starling RC, Ratliff NB, Cook DJ, McCarthy P, Young JB, Yamani MH (2002) Patterns of myocardial endothelin-1 expression and outcome after cardiac transplantation. Circulation 105(15):1768–1771
Moroni C, Tolone S, Bondanini F, Schillaci O, Affricano C, Cassone R, Gaspardone A, Gaudio C (2019) Endothelin-1 in hypertensive patients with ischemic heart disease. Intern Emerg Med. https://doi.org/10.1007/s11739-019-02095-3
Krum H, Viskoper RJ, Lacourciere Y, Budde M, Charlon V (1998) The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. N Engl J Med 338:784–790
Nakov R, Pfarr E, Eberle S (2002) Darusentan: an effective endothelin A receptor antagonist for treatment of hypertension. Am J Hypertens 15:583–589
Webb DJ (2010) DORADO: opportunity postponed: lessons from studies of endothelin receptor antagonists in treatment-resistant hypertension. Hypertension 56:806–807
Bakris GL (2010) Divergent results using clinic and ambulatory blood pressures: report of a darusentan resistant hypertension trial. Hypertension 56:824–830
Idorsia. Drug discovery & clinical development (2019) idorsia https://www.idorsia.com/documents/com/fact-sheets-presentations/fs-clinical-development.pdf
US National Library of Medicine (2019) ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02603809
Segers VF, Gevaert AB, Boen JR, Van Craenenbroeck EM, De Keulenaer GW (2019) Epigenetic regulation of intercellular communication in the heart. Am J Physiol Heart Circ Physiol. https://doi.org/10.1152/ajpheart.00038.2019
Yu L, Yang G, Weng X, Liang P, Li L, Li J, Fan Z, Tian W, Wu X, Xu H, Fang M, Ji Y, Li Y, Chen Q, Xu Y (2015) Histone methyltransferase SET1 mediates angiotensin II–induced endothelin-1 transcription and cardiac hypertrophy in mice. Arterioscler Thromb Vasc Biol 35:1207–1217
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Statements on human and animal rights
This article does not contain any studies with human participants or animals performed by any of the authors.
Informed consent
None.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Ferri, C., Desideri, G. Is circulating endothelin evaluation useful for clinicians?. Intern Emerg Med 14, 1029–1031 (2019). https://doi.org/10.1007/s11739-019-02099-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11739-019-02099-z